Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2626
Triumph Financial Inc
TFIN
$1.49B
| $2.95M | ﹤0.01% |
47,145
+12,805
| +37% | +$717K |
2017 Q1
35 quarters
|
|
2627
Hilltop Holdings
HTH
$2.2B
| $2.94M | ﹤0.01% |
86,677
+18,349
| +27% | +$616K |
2013 Q2
50 quarters
|
|
2628
Autohome
ATHM
$2.37B
| $2.94M | ﹤0.01% |
131,956
+64,398
| +95% | +$1.61M |
2016 Q4
36 quarters
|
|
2629
United States Lime & Minerals
USLM
$3.18B
| $2.93M | ﹤0.01% |
24,497
+1,493
| +6% | +$185K |
2016 Q2
38 quarters
|
|
2630
Toronto Dominion Bank
TD
$193B
| $2.93M | ﹤0.01% |
31,132
-2,218
| -7% | -$187K |
2013 Q2
50 quarters
|
|
2631
Adeia
ADEA
$2.84B
| $2.92M | ﹤0.01% |
169,488
+336
| +0.2% | +$4.98K |
2022 Q1
15 quarters
|
|
2632
Rayonier
RYN
$5.37B
| $2.91M | ﹤0.01% |
134,508
-61,876
| -32% | -$1.4M |
2013 Q2
50 quarters
|
|
2633
Helios Technologies
HLIO
$2.36B
| $2.9M | ﹤0.01% |
54,289
+5,076
| +10% | +$274K |
2023 Q4
8 quarters
|
|
2634
ArcBest
ARCB
$2.96B
| $2.9M | ﹤0.01% |
39,087
-11,298
| -22% | -$804K |
2016 Q2
38 quarters
|
|
2635
PROG Holdings
PRG
$1.23B
| $2.9M | ﹤0.01% |
98,211
+31,806
| +48% | +$948K |
2022 Q1
15 quarters
|
|
2636
AnaptysBio
ANAB
$1.45B
| $2.89M | ﹤0.01% |
59,654
-3,798
| -6% | -$148K |
2017 Q1
35 quarters
|
|
|
SEM
2637
DELISTED
Select Medical
SEM
| $2.88M | ﹤0.01% |
193,774
-4,541
| -2% | -$64.2K |
2013 Q2
50 quarters
|
|
2638
Douglas Emmett
DEI
$1.64B
| $2.88M | ﹤0.01% |
261,738
+16,569
| +7% | +$208K |
2013 Q2
50 quarters
|
|
2639
Atlanta Braves Holdings Series B
BATRK
$3.34B
| $2.88M | ﹤0.01% |
72,900
+6,737
| +10% | +$266K |
2023 Q4
8 quarters
|
|
2640
Napco Security Technologies
NSSC
$1.29B
| $2.88M | ﹤0.01% |
68,958
+13,880
| +25% | +$584K |
2019 Q1
27 quarters
|
|
2641
Ivanhoe Electric
IE
$1.67B
| $2.87M | ﹤0.01% |
179,730
-108,590
| -38% | -$1.55M |
2022 Q2
14 quarters
|
|
2642
Werner Enterprises
WERN
$2.12B
| $2.87M | ﹤0.01% |
95,620
+7,137
| +8% | +$196K |
2013 Q2
50 quarters
|
|
|
SY
2643
So-Young International
SY
$277M
| $2.86M | ﹤0.01% |
1,116,336
+618,709
| +124% | +$2.01M |
2025 Q1
3 quarters
|
|
2644
Knowles
KN
$3.42B
| $2.86M | ﹤0.01% |
133,295
+11,264
| +9% | +$257K |
2014 Q1
47 quarters
|
|
2645
CALL
Comstock Resources
CRK
$3.75B
| $2.85M | ﹤0.01% |
+123,100
| New | +$2.71M |
2025 Q4
0 quarters
|
|
2646
Xeris Biopharma Holdings
XERS
$1.66B
| $2.85M | ﹤0.01% |
362,751
+16,112
| +5% | +$127K |
2022 Q1
15 quarters
|
|
2647
Replimune Group
REPL
$1.23B
| $2.84M | ﹤0.01% |
292,185
-163,677
| -36% | -$1.39M |
2018 Q3
29 quarters
|
|
|
PLGO
2648
Pelagos Insurance Capital
PLGO
$2.01B
| $2.84M | ﹤0.01% |
144,889
+6,202
| +4% | +$116K |
2023 Q2
10 quarters
|
|
|
HOUS
2649
DELISTED
Anywhere Real Estate
HOUS
| $2.83M | ﹤0.01% |
200,197
-25,365
| -11% | -$311K |
2013 Q2
50 quarters
|
|
2650
Dole
DOLE
$1.2B
| $2.83M | ﹤0.01% |
188,831
+4,124
| +2% | +$57.4K |
2022 Q1
15 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.